Abstract:

BACKGROUND: Anti-signal recognition particle (SRP) antibodies are used as serological markers of necrotizing myopathy, which is characterized by many necrotic and regenerative muscle fibers without or with minimal inflammatory cell infiltration. The clinical spectrum associated with anti-SRP antibodies seems to be broad.
OBJECTIVE: To describe the clinical characteristics, autoantibodies status, and neurological outcome associated with anti-SRP antibody.
METHODS: We studied clinical and laboratory findings of 100 patients with inflammatory myopathy and anti-SRP antibodies. Anti-SRP antibodies in serum were detected by the presence of 7S RNA using RNA immunoprecipitation. In addition, enzyme-linked immunosorbent assays (ELISAs) using a 54-kD protein of SRP (SRP54) and 3-hydroxyl-3-methylglutatyl-coenzyme A reductase (HMGCR) were also conducted.
RESULTS: The mean onset age of the 61 female and 39 male patients was 51 years (range 4-82 years); duration ≥ 12 months before diagnosis was seen in 23 cases. All patients presented limbs weakness; 63 had severe weakness, 70 neck weakness, 41 dysphagia, and 66 muscle atrophy. Extramuscular symptoms and associated disorders were infrequent. Creatine kinase levels were mostly more than 1000 IU/L. Histological diagnosis showed 84 patients had necrotizing myopathy, and apparent cell infiltration was observed in 16 patients. Anti-SRP54 antibodies were undetectable in 18 serum samples with autoantibodies to 7S RNA. Anti-HMGCR antibodies were positive in 3 patients without the statin treatment, however, were negative in 5 patients with statin-exposure at disease onset. All but 3 patients were treated by corticosteroids and 62 (77 %) of these 81 patients required additional immunotherapy. After 2-years treatment, 22 (27 %) of these 81 patients had poor neurological outcomes with modified Rankin scale scores of 3-5. Multivariate analysis revealed that pediatric disease onset was associated with the poor outcomes.
CONCLUSION: Anti-SRP antibodies are associated with different clinical courses and histological presentations.

日本語要旨:

抗SRP抗体陽性の壊死性ミオパチーが疑われる患者100名に対し、臨床的所見、自己抗体の調査及び、患者の臨床経過を観察した。その結果、壊死性ミオパチーのマーカーとして用いられる抗SRP抗体を7S RNA及びSRP54・HMGCRを用い免疫沈降/吸着法で検出し、患者の臨床経過や組織学的診断により多様性があることを報告した。また、特に幼児期からの発症患者は予後不良であった。本研究は臨床的に幅広い所見が見られ診断が困難である壊死性ミオパチーはの早期の正しい診断に貢献するものである。